The role of the immune system as an integral component of the inflammatory response in the pathophysiology of migraine remains unclear. The aim of this study was to evaluate the differences in immune system parameters (acquired immunity parameters) in patients with episodic migraine (EM) and in healthy controls. In EM patients, we aimed to determine whether the changes found in peripheral blood parameters were related to migraine severity according to the standardised MIDAS and HIT-6 tests. Forty-nine patients with EM and 50 healthy controls were included in this study. The authors compared different lymphocyte parameters obtained by multicolor flow cytometry in the EM and control groups by performing statistical tests. The relationship between the changes in peripheral blood parameters and migraine severity in EM patients was investigated using correlation and regression analysis. EM patients showed higher values than healthy controls, especially in nine parameters: relative count of lymphocytes, relative and absolute counts of CD3 T cells, relative and absolute counts of CD8 suppressor cytotoxic T cells, relative and absolute counts of CD4 + TEMRA (terminally differentiated helper T lymphocytes), absolute count of CD8 naïve T cells, and absolute count of CD19 switched memory B cells. Among the lymphocyte parameters, CD4 + TEM (effector memory helper T lymphocytes) and CD8 + TEMRA (terminally differentiated cytotoxic T lymphocytes) were statistically significantly associated with HIT-6. Patients with a CD4 + TEM value below 15 had a high probability (90%) that the HIT-6 value would be higher than 60. The results of this study show that EM patients have changes in immune system parameters measured in the peripheral blood. Changes in the abundance of CD4 + TEM could be used as a biomarker for disease severity.

Biomedical Research Center University Hospital Hradec Kralové Hradec Kralové Czech Republic

Department of Chemistry University of Hradec Kralove Hradec Kralove Czech Republic

Department of Clinical Immunology and Allergology University Hospital Hradec Králové Hradec Králové Czech Republic

Department of Neurology Faculty of Medicine University Hospital Hradec Králové Charles University Sokolská 581 Prague Hradec Králové 500 05 Czech Republic

Zobrazit více v PubMed

Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: A disorder of sensory processing. Physiol. Rev. 2017;97:553–622. doi: 10.1152/physrev.00034.2015. PubMed DOI PMC

Steiner T, et al. The impact of headache in Europe: Principal results of the Eurolight project. J. Headache Pain. 2014;15:31. doi: 10.1186/1129-2377-15-31. PubMed DOI PMC

Sokolovic E, Riederer F, Szucs T, Agosti R, Sándor PS. Self-reported headache among the employees of a Swiss university hospital: Prevalence, disability, current treatment, and economic impact. J. Headache Pain. 2013;14:29. doi: 10.1186/1129-2377-14-29. PubMed DOI PMC

Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: Disability and economic costs. Arch Intern. Med. 1999;159:813–818. doi: 10.1001/archinte.159.8.813. PubMed DOI

Pietrobon D, Striessnig J. Neurobiology of migraine. Nat. Rev. Neurosci. 2003;4(5):386–398. doi: 10.1038/nrn1102. PubMed DOI

Kemper RH, Meijler WJ, Korf J, Horst GJ. Migraine and function of the immune system: A meta-analysis of clinical literature published between 1966 and 1999. Cephalalgia. 2001;21:549–557. doi: 10.1046/j.1468-2982.2001.00196.x. PubMed DOI

Moskowitz MA, Reinhard JF, Romero J, Melamed E, Pettibone DJ. Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine? Lancet. 1979;2:883–885. doi: 10.1016/S0140-6736(79)92692-8. PubMed DOI

Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br. J. Pharmacol. 1990;99(1):202–206. doi: 10.1111/j.1476-5381.1990.tb14679.x. PubMed DOI PMC

Connor HE, et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia. 1997;17(3):145–152. doi: 10.1046/j.1468-2982.1997.1703145.x. PubMed DOI

Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 1990;28(2):183–187. doi: 10.1002/ana.410280213. PubMed DOI

Fidan I, Yüksel S, Ymir T, Irkeç C, Aksakal FN. The importance of cytokines, chemokines and nitric oxide in pathophysiology of migraine. J. Neuroimmunol. 2006;171(1–2):184–188. doi: 10.1016/j.jneuroim.2005.10.005. PubMed DOI

Arumugam M, Parthasarathy V. Reduction of CD4(+)CD25(+) regulatory T-cells in migraine: Is migraine an autoimmune disorder? J. Neuroimmunol. 2016;290:54–59. doi: 10.1016/j.jneuroim.2015.11.015. PubMed DOI

Cseh A, et al. Lymphocyte subsets in pediatric migraine. Neurol. Sci. 2013;34:1151–1155. doi: 10.1007/s10072-012-1218-3. PubMed DOI

Grazzi L, Corsini E, Ciusani E, Usai S, Vasco C, Bussone G. Evaluation of immune parameters in chronic migraine with medication overuse. Neurol. Sci. 2014;35:171–173. doi: 10.1007/s10072-014-1763-z. PubMed DOI

Nurkhametova D, et al. Purinergic profiling of regulatory T-cells in patients with episodic migraine. Front. Cell Neurosci. 2018;12:326. doi: 10.3389/fncel.2018.00326. PubMed DOI PMC

Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 33:629–808 (2013). PubMed

Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology. 2001;56:S20–S28. doi: 10.1212/WNL.56.suppl_1.S20. PubMed DOI

Bayliss MS, et al. A study of the feasibility of Internet administration of a computerized health survey: The headache impact test (HIT) Qual. Life Res. 2003;12:953–961. doi: 10.1023/A:1026167214355. PubMed DOI

Kosinski M, et al. A six-item short-form survey for measuring headache impact: The HIT-6. Qual. Life Res. 2003;12:963–974. doi: 10.1023/A:1026119331193. PubMed DOI

Tian Y, et al. Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA. Nat. Commun. 2017;8:1473. doi: 10.1038/s41467-017-01728-5. PubMed DOI PMC

Zhang N, Bevan MJ. CD8(+) T cells: Foot soldiers of the immune system. Immunity. 2011;35:161–168. doi: 10.1016/j.immuni.2011.07.010. PubMed DOI PMC

Salou M, Nicol B, Garcia A, Laplaud D-A. Involvement of CD8(+) T cells in multiple sclerosis. Front. Immunol. 2015;6:604. doi: 10.3389/fimmu.2015.00604. PubMed DOI PMC

Covelli V, Maffione AB, Munno I, Jirillo E. Alterations of nonspecific immunity in patients with common migraine. J. Clin. Lab. Anal. 1990;4:9–15. doi: 10.1002/jcla.1860040105. PubMed DOI

Rosenblum MD, Way SS, Abbas AK. Regulatory T cell memory. Nat. Rev. Immunol. 2016;16:90–101. doi: 10.1038/nri.2015.1. PubMed DOI PMC

Rattik S, et al. Elevated circulating effector memory T cells but similar levels of regulatory T cells in patients with type 2 diabetes mellitus and cardiovascular disease. Diab. Vasc. Dis. Res. 2019;16:270–280. doi: 10.1177/1479164118817942. PubMed DOI

Yap M, et al. Expansion of highly differentiated cytotoxic terminally differentiated effector memory CD8+ T cells in a subset of clinically stable kidney transplant recipients: A potential marker for late graft dysfunction. J. Am. Soc. Nephrol. 2014;25:1856–1868. doi: 10.1681/ASN.2013080848. PubMed DOI PMC

Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708–712. doi: 10.1038/44385. PubMed DOI

Pusic AD, Pusic KM, Clayton BL, Kraig RP. IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination. J. Neuroimmunol. 2014;266(1–2):12–23. doi: 10.1016/j.jneuroim.2013.10.014. PubMed DOI PMC

Pusic AD, Mitchell HM, Kunkler PE, Klauer N, Kraig RP. Spreading depression transiently disrupts myelin via interferon-gamma signaling. Exp. Neurol. 2015;264:43–54. doi: 10.1016/j.expneurol.2014.12.001. PubMed DOI PMC

Leao AAP. Spreading depression of activity in the cerebral cortex. J. Neurophysiol. 1944;7:359–390. doi: 10.1152/jn.1944.7.6.359. PubMed DOI

Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu. Rev. Physiol. 2013;75:365–391. doi: 10.1146/annurev-physiol-030212-183717. PubMed DOI

Cui Y, Kataoka Y, Watanabe Y. Role of cortical spreading depression in the pathophysiology of migraine. Neurosci. Bull. 2014;30(5):812–822. doi: 10.1007/s12264-014-1471-y. PubMed DOI PMC

Pusic KM, Won L, Kraig RP, Pusic AD. IFNγ-stimulated dendritic cell exosomes for treatment of migraine modeled using spreading depression. Front. Neurosci. 2019;13:942. doi: 10.3389/fnins.2019.00942. PubMed DOI PMC

Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001;69(3):89–95. doi: 10.1067/mcp.2001.113989. PubMed DOI

Durham P, Papapetropoulos S. Biomarkers associated with migraine and their potential role in migraine management. Headache. 2013;53(8):1262–1277. doi: 10.1111/head.12174. PubMed DOI

Ferroni P, et al. Circulating biomarkers in migraine: New opportunities for precision medicine. Curr. Med. Chem. 2019;26(34):6191–6206. doi: 10.2174/0929867325666180622122938. PubMed DOI

Cernuda-Morollón E, Ramón C, Martínez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain. 2015;156:820–824. doi: 10.1097/j.pain.0000000000000119. PubMed DOI

Sarchielli P, et al. Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia. 2006;26(3):257–265. doi: 10.1111/j.1468-2982.2005.01016.x. PubMed DOI

Terrazzino S, et al. The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. Eur. J. Pharmacol. 2010;641(2–3):82–87. doi: 10.1016/j.ejphar.2010.04.049. PubMed DOI